The Gyrus TM system uses bipolar electrocautery with saline irrigation to vaporize prostatic tissue and is compared to transurethral resection of the prostate (TURP) in a randomized prospective study with 1 y follow-up. Outcomes measured were fluid absorption, blood loss, period of catheterization, hospital stay, symptom scores, quality of life, flow rates, and post-void residual volumes at 3, 6, and 12 months. All measured parameters were similar, although re-catheterization rates were higher (30% vs 5%) in the Gyrus group. Clot evacuation rates were higher in the TURP group (19% vs 0%). The Gyrus TM device is safe and produces results that are similar to TURP at 1 y.
Introduction
Transurethral resection of the prostate (TURP) is currently the most frequently performed operation for men with lower urinary tract symptoms (LUTS) thought to be secondary to benign prostatic hypertrophy (BPH). However, perioperative electrolyte disturbances (TUR syndrome) and haemorrhage are recognized complications. 1 Furthermore, TURP systems utilize monopolar electrical currents that can cause nervous stimulation and, in rare circumstances, burns and problems with cardiac pacemakers. In addition, monopolar systems are not efficient for simultaneously cutting and coagulating prostatic tissue.
The Gyrus TM device has recently been shown to be an effective and safe system. 2 This instrument creates a cavity in the prostate similar to that achieved with the conventional resectoscope. The system uses bipolar currents that have several possible advantages. First, the prostatic ablation is performed using saline irrigation minimizing the electrolyte problems that are frequently recognized with glycine, mannitol, and water systems. 3 Second, the absence of a return current removes the risks of nervous stimulation, burns, and cardiac pacemaker problems. Third, the ability to improve the 'coupling' of the cut and coagulation modes may result in less haemorrhage. As such, the operative procedure may be technically easier and the need for postoperative irrigation reduced. In turn, recovery may be quicker and hospital stays shorter than with conventional TURP. However, to date, no randomized trials evaluating these aspects of the surgical procedures have been reported. The aim of this study was to compare the Gyrus TM system with TURP. The outcomes measured were perioperative bleeding and electrolyte changes, length of time for postoperative catheterization and hospital stay. Efficacies in terms of symptom improvement, flow rates, and postvoid residual volumes were also evaluated at 3, 6, and 12 months following surgery.
Materials and methods

Gyrus TM device
Gyrus TM is a bipolar device that works in an isotonic saline medium. The anaesthetic requirements and surgical set-up are also similar to that for a standard TURP; continuous flow operating scopes and videoscopy are used. The clear difference between resection and vaporization techniques is that tissue for histological analysis is not obtained with the latter.
The active electrode comprises an iridium/platinum alloy in a 20:80 proportion. This is separated from the stainless-steel return electrode by a ceramic insulator. Both electrodes are placed on the same axis, which facilitates the active-to-return current. This latter feature enhances the vaporization and haemostatic properties of the device. Furthermore, the geometric configuration of the active electrode increases the ratio of the 'contact' areas of the active to the return electrode, which in turn, produces very high local power densities that facilitate tissue vaporization (Figure 1 ). Specifically, a vapour pocket is produced at the tip of the device, which has a low thermal mass and a very high temperature. When the vapour pocket is brought into contact with the prostate, a large amount of energy is discharged into the tissue, causing vaporization. The electric current passes to the return electrode through the saline medium (path of lowest impedance). Tissue is removed only up to the boundary of the vapour pocket and so a well-delineated trench is created. Furthermore, as the electric current does not pass through the patient to reach the return electrode, deep heating of the prostate is moderate, and the area of coagulation necrosis measured as 1 mm. 3 The surgical technique differs from a conventional resection in two major respects. First, the prostatic cavity is modelled with a circumferential action rather like 'peeling the rings of an onion' from inside to outside. Second, activation of the current is necessary prior to bringing the electrode in contact with the tissue (this allows the vapour pocket to build up). However, despite these two practical differences, our experience is that the technique is very rapidly learned by those used to performing endoscopic resections.
A prostatic cavity very similar to that obtained by TURP can be created. Blood loss is minimized and accurate delineation of the surgical landmarks is the same as for a conventional resection.
Study design
The primary outcome measure was the period of catheterization. A difference of 6 h less than the mean catheter period (37 h) was considered to be a meaningful difference, as for four-fifths of men this translated into a discharge that occurred one working day earlier. This was based on in-house audit data for TURP, where the mean (s.d.) length for hospital stay was 37 h (716 h). Furthermore, a pilot study of six patients suggested that the mean catheter period for the Gyrus TM device was 28 h (710 h). Powering the study to detect a difference of this magnitude, we aimed to randomize 120 men. The decision to remove the catheter was made by the wardnursing staff who were blind to the surgical modality used, and who were guided by comparing the colour of the catheter effluent with a visual chart. A study to actually evaluate lengths of hospital stay could not be designed, as estimates for confounding variables such as early recatheterization rates for the Gyrus TM device were not available from the published literature. Lengths of hospital stay and recatheterization rates were therefore secondary outcomes to be explored. Likewise, the amount of irrigant used, the length of time irrigation was required (in hours), and pre-and perioperative measures (in the recovery room and at 24 h) of haematocrit of irrigant fluid, serum haematocrit, [Na + ], and haemoglobin were all considered to be indirect indices of bleeding and fluid absorption. Haematocrit of the effluent irrigation fluid was measured using Haemocue s (g/l). Treatment efficacy was evaluated at baseline, 3, 6, and 12 months by comparing flow rates, post-void residual volumes, AUA symptom scores, quality of life (QoL) scores, and a sexual function questionnaire. The AUA symptom score used was that described in section A of the original AUA-7 4 and comprises seven domains with five possible responses to 
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Inclusion criteria were men less than 80 y of age, presenting to the outpatient clinic with LUTS considered to be secondary to BPH and considered to be appropriate for TURP. Patients were then given the option to participate after assimilating written information that had been approved by the local ethics committee, and following a further discussion with one of the coinvestigators. Exclusions included men presenting with acute urinary retention, anticoagulant therapy, prostate volume greater than 80 cm 3 , previous prostatic surgery, or suspicion of prostate cancer. The latter included men with a PSA 4 4 ng/ml (unless biopsies were negative for cancer).
Randomization was made in the pre-anaesthetic room by drawing a chit from a previously sealed box containing an equal number of tickets for the two surgical modalities. At baseline, the study groups were fairly well matched for age, QoL, flow rates, and post-void residual volumes. AUA symptom scores were slightly higher in the Gyrus TM group (Table 1) .
Results
This is a preliminary report of an ongoing randomized controlled trial. To date, 51 patients have been randomized, with 40 men (78%) having completed the study (Table 2 ). In general, procedures with the Gyrus TM device took slightly longer (33 vs 26 min). There was no difference in the mean requirements for irrigation, period of catheterization, or hospital stay (Table 3) . No patients in the Gyrus TM group required manual clot evacuation in comparison to 4 of 21 (19%) men undergoing TURP. Ten of the 30 men having the Gyrus TM procedure required recatheterization in comparison to 1 of the 21 in the TURP group (30% vs 5%). In each case, the recatheterization was necessary because of an inability to void (rather than severe dysuria, which has been a feature of other energy delivery systems such as monopolar vaporization and laser devices). All patients voided successfully following catheter removal approximately 2 weeks later (range 14-19 days).
No differences were noted in the haematocrit of the effluent fluid at the conclusion of the procedure. Transient differences were noted in the serum haematocrit, [Na + ], and haemoglobin concentrations in the recovery room suggestive of increased fluid absorption in the TURP group. However, this was no longer apparent by the first postoperative day (Figure 2(a-c) ). Improvements in flow rates, post-void residual urine volumes, AUA symptom scores, and QoL were comparable between the two groups ( Figure 3(a-d) ). An interesting yet unexplained observation was that QoL measures at 3 months, for both procedures, were worse than preoperatively. Although this appeared to improve, at 1 y, QoL measures were still inferior to the preoperative baseline (Figure 3(b) ).
Discussion
This is a preliminary report of the first 40 men who have completed the 1 y period of study in an ongoing randomized clinical trial comparing bipolar electrovaporization of the prostate with TURP. So far, the results suggest that there is little difference between the two surgical techniques. Although the study has been powered to detect a difference in the period of postoperative catheterization, it seems that thus far no major differences are apparent. However, several observations make this study worthy of early report. First, nearly onethird of men in the Gyrus TM arm required recatheterization. Second, although there was evidence of reduced fluid absorption with the Gyrus TM device, this was transient and of little apparent clinical significance. Third, we were unable to detect a significant difference in blood loss as determined by the haematocrit of the immediate postoperative effluent, or the circulating haematocrit or haemoglobin on the first postoperative day. Finally, the need for manual clot evacuation in the TURP arm was considerably greater. However, these early findings should be considered carefully within the context of the patient population under study. First, no patient in the study received a blood transfusion. Second, most prostate glands were of small to moderate size (mean TRUS volume B40 cm 3 ). Third, resection times were short (B30 min) and resection weights were generally less than 10 g (Table 3 ). So far, therefore, it would appear that there is little difference between these techniques for those men with small prostates. However, given the observed differences described above, it would not be unreasonable to hypothesize that the Gyrus TM device may have considerable advantages in certain well-defined circumstances. First, the transient but demonstrable differences in serum haematocrit, [Na + ] and haemoglobin concentrations in the recovery room may be of benefit to those men who have a high risk of congestive cardiac failure in whom fluid absorption is clearly undesirable. Second, the reduced incidence of postoperative clot retention may result in a marked benefit for those individuals where an increased blood loss might be anticipated. Examples of the latter would include patients with haemopoeitic coagulopathies, men taking asprin, or those on anticoagulant therapy. However, both these hypotheses remain to be tested. Furthermore, any putative advantages must also be tempered by the clear finding of an increased rate of recatheterization observed in those undergoing the Gyrus TM electrovaporization procedure. In addition, the slightly longer operation times and lack of tissue for histological analysis may be considered to be unfavourable features of the Gyrus TM device. Our study has not included a cost-benefit analysis. At inception, the cost of the electrodes had not been fixed and, as essentially the same equipment was to be used, such an analysis would only have been dissimilar if lengths of hospital stay differed significantly. However, with the unexpected high recatheterization rates in the Gyrus TM arm, such an analysis becomes desirable and we would urge other investigators to give this consideration. Notwithstanding, we have been able to show that for men with small prostates, there is generally little difference between the two surgical techniques. In particular, the long-term efficacies in terms of symptom improvement, QoL, flow rates, and post-void residual volumes are comparable 1 y following surgery. In short, our findings suggest that a trial comparing the two surgical techniques for men with large prostates, including a cost-benefit analysis, may be worthwhile. 
